FUNDSMITH
28.11.2022 09:01:35 CET | Business Wire | Press release
FundRock Management Company, a leading European third-party UCITS Management Company (“ManCo”) and Alternative Investment Fund Manager (“AIFM”), announces the expansion of its relationship with leading fund management company Fundsmith LLP, to now include distribution services.
FundRock enables clients to streamline their operations in a cost-effective manner by offering third-party ManCo and fund distribution services under one roof, complemented by a wide range of fund administration, middle office, banking, depositary and custody services delivered through parent company Apex Group.
In addition to existing ManCo services, FundRock Distribution S.A. will now provide distribution services, enabling Fundsmith LLP to distribute its funds in the EU.
FundRock’s established network of more than 200 experts in key jurisdictions including Luxembourg, the United Kingdom, Ireland, Netherlands, France, Italy, Switzerland, Germany, Abu Dhabi and Singapore delivers significant time, resource and cost benefits.
Arnaud Gérard, CFA, Head of Distribution at FundRock, commented: “FundRock Distribution offers a powerful solution for asset managers, providing local knowledge combined with an established network of contacts, enabling our clients to focus on their core business. We look forward to supporting Fundsmith to distribute their funds more efficiently and effectively in EU markets, while ensuring the highest standards of governance and regulatory compliance.”
Mark Laurence, COO at Fundsmith, commented: “We are delighted to extend our existing relationship with FundRock to help manage our post Brexit EU distribution. In particular it will allow us to target the Italian market through the services of incoming FundRock Sales Director, Giuseppe Bellavia, who joins from Allianz Global Life and has been appointed as Sales Director of FundRock to lead distribution for Fundsmith in Italy.”
About Fundsmith SICAV
Fundsmith SICAV is the umbrella fund for Fundsmith Equity Fund and Fundsmith Sustainable Equity Fund.
Fundsmith Equity Fund, a sub-fund of the Fundsmith SICAV, is managed with exactly the same process as the same-named, largest active equity fund in the UK. Fundsmith Equity Fund offers investors a high quality, concentrated portfolio of 20-30 resilient, global growth companies which are held for the long term.
The Fundsmith Equity Fund takes sustainability risk and ESG characteristics into account as part of its selection process. In that respect, the Fundsmith Equity Fund promotes environmental and/or social characteristics within the meaning of Article 8 of SFDR. Fundsmith Equity Fund is rated Gold by Morningstar and has a four crown FE fundinfo rating.
Fundsmith Sustainable Equity Fund is also an Article 8 fund and it follows the same strategy as Fundsmith Equity Fund but with an important difference, namely the following sectoral exclusions that are stipulated in the fund prospectus:
- No Aerospace and Defence
- No Brewers, Distillers and Vintners
- No Casinos and Gaming
- No Gas and Electric Utilities
- No Metals and Mining
- No Oil, Gas and Consumable Fuels
- No Pornography
- No Tobacco
In addition, investments are screened for sustainability in the widest sense, taking account not only the companies’ handling of environmental, social and governance policies and practices but also their policies and practices on research and development, new product innovation, dividend policy and the adequacy of capital investment. Fundsmith Sustainable Equity Fund has a LuxFLAG ESG Label, which has the primary objective to reassure investors that the investment product incorporates ESG criteria throughout the entire investment process while screening 100% of their invested portfolio according to one of the ESG strategies and standards recognised by LuxFLAG.
Terry Smith, Portfolio Manager of Fundsmith Equity Fund and Fundsmith Sustainable Equity Fund, commented: “We will only invest in companies that have attractive valuations, high barriers to entry and are extremely resilient. We like companies with a business advantage that is hard to replicate and which are resilient to change, particularly to technological change. The kind of intangible assets we seek are brand names, high market shares, patents, licenses, distribution networks, installed bases and client relationships. We especially like companies that produce goods which are consumed at short and regular intervals and which sell directly to consumers. A company that sells many small items every day is better able to earn more consistent returns over time than a company whose business is cyclical, like a steel manufacturer, or “lumpy”, like a property developer or which sells items that are expensive and durable like a motor manufacturer."
Terry Smith, founder of Fundsmith, is the portfolio manager of Fundsmith Equity Fund and Fundsmith Sustainable Equity Fund. Terry is well-known for his straight talking and clear three step investment strategy that seeks to buy good companies, not overpay and do nothing.
Since inception of the Fundsmith Equity Fund in the UK in 2010 to the end of October 2022, the fund’s assets have grown to over £22 billion and it has delivered a total return of over 460% or 15.5% annualised, net of fees.
Fundsmith Equity Fund, a sub-fund of the Fundsmith SICAV, has growth its assets under management to over €8bn and it has delivered a total return since its inception in 2011 of over 399.7% or 15.8% annualised, net of fees.
Terry Smith added: “We have grown Fundsmith Equity Fund into the UK’s largest active equity fund, built on our successful strategy of investing in a small number of high quality companies that can be held for the long term. While our strategy is simple, it requires rigorous analysis and strict discipline to deliver superior returns over the long-term at a reasonable cost.
“We established our SICAV in Luxembourg in 2011 and are pleased to have extended our relationship with FundRock so we can actively distribute across the EU, in particular targeting Italy with the expertise of FundRock Sales Director Giuseppe Bellavia.”
FUND FACTS
MINIMUM INVESTMENT: €2,000
CHARGES:
No initial charge
No performance fee
No redemption fees
Annual Management Fee 1%
Estimated OCF – Fundsmith Equity Fund 1.09%
Estimated OCF – Fundsmith Sustainable Equity Fund 1.12%
UNITS: Income or Accumulation
-Ends-
About FundRock Distribution S.A.
FundRock Distribution S.A., a subsidiary of the Apex Group, is authorised by the Luxembourg regulator, the CSSF, to act as investment adviser and distributor of shares/ units of funds. Under this MiFID license, FundRock is able to act as global distributor/sub-distributor of the funds managed by our affiliates. They leverage their free provision of services (passport) through the European Union to offer a long term and stable solution to our clients. FundRock offers a more flexible and economical go to market solution including, streamlined access to fund platforms, fund distribution support and direct representation.
FundRock Distribution S.A. is a subsidiary of FundRock Management Company S.A., a leading independent UCITS management company and AIFM investment fund manager. As of September 2022, FundRock oversees more than 500 funds with a total of €116 billion in assets under management, including Italian domiciled funds. The FundRock group has more than 200 employees in eight countries including Luxembourg, United Kingdom, Ireland, France, Switzerland, Abu Dhabi and Singapore.
About Fundsmith
Fundsmith is focused on delivering superior investment performance at a reasonable cost. It was established to be different from its peers so as to achieve a different result in line with Sir John Templeton’s axiom that “If you want to have a better performance than the crowd, you must do things differently from the crowd.” The rigorous research process of Fundsmith is central to what we do. We apply exacting standards to potential investments to produce a portfolio of resilient businesses with excellent performance. Minimising the costs we incur on behalf of our customers in implementing our strategy also sits at the heart of our philosophy.
Fundsmith was established in 2010 by Terry Smith. The business is owned and controlled by its partners, who have worked closely together over many years, and is headquartered in London with offices in Mauritius and Connecticut, USA. It is structured to survive Terry Smith’s demise and continue with the same investment philosophy. All partners of the firm have a significant coinvestment in our Funds delivering a clear alignment of interest. Ancillary activities are outsourced to some of the world's leading providers in order to deliver high quality operations whilst allowing the Fundsmith team to focus on the investment analysis and portfolio management and customer care.
www.fundsmith.eu
www.fundsmith.eu/fsef/
Fundsmith SICAV is an investment company organised under the laws of the Grand Duchy of Luxembourg as a societé d’investissement à capital variable, is governed by Part I of the UCI Law and qualifies as a UCITS.
Before making any investment decisions, please refer to the Prospectus and Key Investor Information Document (KIID)s in English, Danish, Dutch, French, German, Italian, Norwegian, Portuguese, Spanish and Swedish, available on the Fundsmith SICAV website https://www.fundsmith.eu/documents/.
A summary of your investor rights can be found in English here, https://www.fundsmith.eu/investor-rights. Past performance is not necessarily a guide to future performance. The value of investments and the income from them may fall as well as rise and be affected by changes in exchange rates, and you may not get back the amount of your original investment.
Issued 1 Sep 2022 within Europe (ex-Switzerland) by FundRock Distribution S.A. (“FRD”) the EU distributor for Fundsmith SICAV. FRD is a public limited company, incorporated under the laws of the Grand Duchy of Luxembourg, registered office at 9A, rue Gabriel Lippmann, L-5365 Munsbach, Luxembourg, and registered with the Luxembourg trade and companies register under number B253257. FRD is authorized as distributor of shares/units of UCIs without making or accepting payments (within the meaning of Article 24-7 of the 1993 Law), as updated from time to time. FRD is authorised and regulated by the Commission de Surveillance du Secteur Financier (CSSF).
Please note that FundRock Management Company S.A. may decide to terminate the arrangements made for the marketing of the Fund under the denotification process in new Cross-border Distribution Directive (Directive (EU) 2019/1160).
This is a marketing communication.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005425/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
